Danish pharmaceutical giant Novo-Nordisk A/S released its financial report on Wednesday.
According to Zhitong Finance APP, on Wednesday, Danish pharmaceutical giant Novo-Nordisk A/S (NVO.US) announced its third-quarter financial results for 2025. Third-quarter sales (at constant exchange rates) increased by 11% year-over-year to DKK 74.976 billion; operating profit (at constant exchange rates) decreased by 21% year-over-year to DKK 23.682 billion; net profit amounted to DKK 20.006 billion, a year-over-year decrease of 27%.
The financial report showed that Novo-Nordisk A/S's sales from diabetes and weight loss drug businesses in the third quarter reached DKK 70.26 billion. Among these, Ozempic’s sales were DKK 30.74 billion; oral GLP-1 drug Rybelsus’ sales were DKK 5.44 billion; Wegovy’s sales were DKK 20.35 billion. Semaglutide, known as the 'blockbuster drug,' generated sales of DKK 169.296 billion (USD 25.4 billion) in the first three quarters, surpassing Keytruda (USD 23.3 billion) and Eli Lilly and Co's tirzepatide (USD 24.8 billion).
Meanwhile, the company updated its earnings guidance. Novo-Nordisk A/S stated that, at constant exchange rates (CER), sales for 2025 are expected to grow by 8%-11%, and operating profit is projected to increase by 4%-7%.
Novo-Nordisk A/S CEO Mike Doustdar stated that the company is adopting an aggressive strategy to streamline its organizational structure and refocus on core businesses in diabetes and weight management. Previously, Novo-Nordisk A/S raised its acquisition offer for U.S.-based weight loss startup Metsera (MTSR.US), with the latest bid reaching USD 10 billion. Metsera is considered one of the most promising companies in the weight loss drug sector and is developing several experimental weight loss drugs, including an innovative drug with a potentially lower injection frequency than existing products from Novo-Nordisk A/S and Eli Lilly and Co.
